Find Merimepodib manufacturers, exporters & distributors on PharmaCompass

Merimepodib

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

15 Drugs in Development

15 Drugs in Development

DIGITAL CONTENT

5 NEWS #PharmaBuzz

media
5 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

15DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 198821-22-6, Vx-497, Mmpd, Vi-21497, 2zl2ba06fu, (s)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate

Molecular Formula

C₂₃H₂₄N₄O₆

Molecular Weight

452.5 g/mol

InChI Key

JBPUGFODGPKTDW-SFHVURJKSA-N

FDA UNII

2ZL2BA06FU

Merimepodib is an inosine monophosphate dehydrogenase (IMPDH) inhibitor with activity against hepatitis C virus (HCV). IMPDH catalyzes the rate-limiting step in the de novo synthesis of guanine nucleotides, and treatment with merimepodib reduces the intracellular guanine nucleotide levels that are required for RNA and DNA synthesis, resulting in antiproliferative and antiviral effect.

1 2D Structure

Merimepodib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate

2.1.2 InChI

InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1

2.1.3 InChI Key

JBPUGFODGPKTDW-SFHVURJKSA-N

2.1.4 Canonical SMILES

COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)OC3CCOC3)C4=CN=CO4

2.1.5 Isomeric SMILES

COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4

2.2 Other Identifiers

2.2.1 UNII

2ZL2BA06FU

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic Acid Tetrahydrofuran-3-yl Ester

2. Vx 497

3. Vx-497

2.3.2 Depositor-Supplied Synonyms

1. 198821-22-6

2. Vx-497

3. Mmpd

4. Vi-21497

5. 2zl2ba06fu

6. (s)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate

7. Vi-21,497

8. Chembl304087

9. [(3s)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate

10. Vx497

11. Merimepodib, Vi-21497, Vx-497

12. (s)-tetrahydro-3-furyl (m-(3-(3-methoxy-4-(5-oxazolyl)phenyl)ureido)benzyl)carbamate

13. Carbamic Acid, ((3-((((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)-, (3s)-tetrahydro-3-furanyl Ester

14. Vx 497

15. Merimepodib [usan:inn]

16. Unii-2zl2ba06fu

17. Merimebodib

18. Carbamic Acid, [[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3s)-tetrahydro-3-furanyl Ester

19. Merimepodib [usan]

20. Merimepodib [mi]

21. Merimepodib [inn]

22. Merimepodib (usan/inn)

23. Merimepodib [who-dd]

24. Schembl329922

25. Gtpl10741

26. Dtxsid70173639

27. [[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamic Acid (3s)-tetrahydro-3-furanyl Ester

28. Bcp28336

29. Ex-a1201

30. Yha82122

31. Zinc3975663

32. Bdbm50102249

33. Fd5020

34. Mfcd09837807

35. S6689

36. Db04862

37. N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic Acid Tetrahydrofuran-3-yl Ester

38. Ncgc00378589-01

39. Ac-35396

40. As-75124

41. Hy-13986

42. D04936

43. A919457

44. Q1727082

45. (3s)-oxolan-3-yl N-{[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate

46. [(3s)-tetrahydrofuran-3-yl] N-[[3-[(3-methoxy-4-oxazol-5-yl-phenyl)carbamoylamino]phenyl]methyl]carbamate

47. {3-[3-(3-methoxy-4-oxazol-5-yl-phenyl)-ureido]-benzyl}-carbamic Acid (s)-(tetrahydro-furan-3-yl) Ester

48. {3-[3-(3-methoxy-4-oxazol-5-yl-phenyl)-ureido]-benzyl}-carbamic Acid Tetrahydro-furan-3-yl Ester

49. Carbamic Acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3s)-tetrahydro-3-furanyl Ester

50. N-[3-3-[3-methoxy-4-(5-oxazolyl)phenyl]ureido]benzyl]carbamic Acid Tetrahydrofuran-3-(s)-yl Ester

2.4 Create Date

2005-08-01

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₄N₄O₆
Molecular Weight	452.5 g/mol
XLogP3	2.1
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	8
Exact Mass	452.16958450 g/mol
Monoisotopic Mass	452.16958450 g/mol
Topological Polar Surface Area	124 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	652
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

For the treatment of hepatitis C virus (HCV) infection.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Merimepodib, an oral drug, contains a novel inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme responsible for stimulating the production of lymphocytes. Merimepodib has the potential to exert direct antiviral activity, as well as affect the immune response by acting on lymphocyte migration and proliferation. Consequently, merimepodib may be an effective treatment for hepatitis C virus (HCV) infection, as the disease involves both viral proliferation and liver inflammation.

5.2 Mechanism of Action

Merimepodib is a orally active inhibitor of inosine monophospate dehydrogenase (IMPDH). IMPDH inhibition leads to a reduction in intracellular guanosine triphosphate (GTP), a molecule required for DNA and RNA synthesis.

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Merimepodib Manufacturers

A Merimepodib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Merimepodib, including repackagers and relabelers. The FDA regulates Merimepodib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Merimepodib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Merimepodib Suppliers

A Merimepodib supplier is an individual or a company that provides Merimepodib active pharmaceutical ingredient (API) or Merimepodib finished formulations upon request. The Merimepodib suppliers may include Merimepodib API manufacturers, exporters, distributors and traders.

Merimepodib GMP

Merimepodib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Merimepodib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Merimepodib GMP manufacturer or Merimepodib GMP API supplier for your needs.

Merimepodib CoA

A Merimepodib CoA (Certificate of Analysis) is a formal document that attests to Merimepodib's compliance with Merimepodib specifications and serves as a tool for batch-level quality control.

Merimepodib CoA mostly includes findings from lab analyses of a specific batch. For each Merimepodib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Merimepodib may be tested according to a variety of international standards, such as European Pharmacopoeia (Merimepodib EP), Merimepodib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Merimepodib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.